1. Home
  2. INAB vs VVOS Comparison

INAB vs VVOS Comparison

Compare INAB & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.38

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Logo Vivos Therapeutics Inc.

VVOS

Vivos Therapeutics Inc.

HOLD

Current Price

$1.45

Market Cap

15.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
VVOS
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
15.1M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
INAB
VVOS
Price
$1.38
$1.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$6.25
AVG Volume (30 Days)
70.9K
160.2K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
80.07
EPS
N/A
N/A
Revenue
N/A
$15,031,000.00
Revenue This Year
N/A
$31.42
Revenue Next Year
N/A
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.91
52 Week Low
$0.12
$1.09
52 Week High
$4.20
$7.40

Technical Indicators

Market Signals
Indicator
INAB
VVOS
Relative Strength Index (RSI) 40.39 59.93
Support Level $1.35 $1.44
Resistance Level $2.14 $1.48
Average True Range (ATR) 0.10 0.13
MACD -0.00 0.03
Stochastic Oscillator 33.33 79.12

Price Performance

Historical Comparison
INAB
VVOS

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Share on Social Networks: